

EVALUATION FORM
Extracorporeal Photopheresis: Defining a Role in the Treatment of Chronic GvHD
Program ID: 07144

The Medical College of Wisconsin respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. *You must complete this evaluation form to receive a CME credit certificate.*

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor

Extent to Which Program Activities Met the Identified Objectives

Through this activity, symposium speakers will:

- | | | | | | |
|---|---|---|---|---|---|
| ◆ Provide an update on current company-sponsored trials using photopheresis in patients with GvHD. | 5 | 4 | 3 | 2 | 1 |
| ◆ Review the results of ongoing investigator-initiated studies using photopheresis to treat patients with GvHD. | 5 | 4 | 3 | 2 | 1 |
| ◆ Outline current plans for future photopheresis studies in GvHD. | 5 | 4 | 3 | 2 | 1 |

Overall Effectiveness of the Activity

- | | | | | | |
|--|---|---|---|---|---|
| Was timely and will influence how I practice | 5 | 4 | 3 | 2 | 1 |
| Will assist me in improving patient care | 5 | 4 | 3 | 2 | 1 |
| Fulfilled my educational needs | 5 | 4 | 3 | 2 | 1 |
| Avoided commercial bias or influence | 5 | 4 | 3 | 2 | 1 |

Impact of the Activity

The information presented:
(check all that apply)

- | | |
|--|--|
| <input type="checkbox"/> Reinforced my current practice/treatment habits | <input type="checkbox"/> Will improve my practice/patient outcomes |
| <input type="checkbox"/> Provided new ideas or information I expect to use | <input type="checkbox"/> Enhanced my current knowledge base |

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

How committed are you to making these changes?

5 (Very committed) 4 3 2 1 (Not at all committed)

Future Activities

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

Follow-up

As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I would be interested in participating in a follow-up survey
- No, I'm not interested in participating in a follow-up survey

Additional comments about this activity:

If you wish to receive acknowledgement of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation and fax to the Office of Continuing Professional Education, 414-456-6623, or mail to Office of Continuing Medical Education, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226. (Note: Persons who claimed CME credit for attending the original presentations on which this program was based (at the BMT Tandem Meetings in February, 2007) may not claim additional credit for participating in this activity.)

Post-test Answer Form

1	2	3	4	5	6	7	8	9

Request for Credit

Name _____ Degree _____

Organization _____ Specialty _____

Address _____

City, State, Zip _____

Telephone _____ Fax _____ E-Mail _____

I certify my actual time spent to complete this educational activity to be:

- I participated in the entire activity and claim 1.0 credits.
- I participated in only part of the activity and claim _____ credits.

Signature _____ Date _____

CME Questions

Extracorporeal Photopheresis: Defining a Role in the Treatment of Chronic GvHD

1. The clinical effects of ECP in cGVHD include:
 - a. improvement in skin disease
 - b. steroid sparing
 - c. healing of mucosal ulcerations
 - d. all of the above

2. The mechanism of action of ECP in cGVHD could include
 - a. apoptosis of treated T-lymphocytes
 - b. modulation of dendritic cell function
 - c. induction of immunoregulatory T-cells
 - d. all of the above

3. The risks of ECP treatment in patients with cGVHD include
 - a. toxicity from methoxpsoralen
 - b. immune activation
 - c. infection from central access catheters
 - d. altered metabolism of immunosuppressive agents

4. Which of the following statements is correct:
 - a. Preventing acute GVHD always leads to prevention of chronic GVHD
 - b. Acute GVHD is not related to the incidence of chronic GVHD
 - c. Preventing acute GVHD does not necessarily prevent chronic GVHD
 - d. The incidence of chronic GVHD is higher in patients without a history of acute GVHD

5. Phase 2 and 3 studies of extracorporeal photopheresis (ECP) in chronic GVHD suggest that:
 - a. ECP has a high response rate in chronic GVHD of the skin, particularly in forms with sclerosis
 - b. ECP has no activity in chronic GVHD
 - c. ECP is most active in GI GVHD
 - d. ECP should not be used in the treatment of chronic GVHD

6. Corticosteroids are:
 - a. Inactive in the management of chronic GVHD
 - b. The single best therapy for the treatment of chronic GVHD, although responses for initial treatment are only about 50-60%
 - c. More effective when given in association with calcneurin inhibitors in the treatment of chronic GVHD
 - d. None of the previous statements are correct

7. What are the NIH criteria for the clinical diagnosis of chronic GVHD?
- Distinction from acute GVHD
 - Presence of at least one diagnostic clinical manifestation OR at least one distinct manifestation confirmed by pertinent biopsy or other relevant tests
 - Exclusion of other possible diagnosis for the clinical manifestation (i.e., infection, drug effect, others)
 - All the above
8. A patient with a prior history of resolved gut and skin acute GVHD develops new onset of isolated erythematous skin rash and diarrhea with a positive biopsy for GVHD after day 100 after transplant. This patient should be classified as having recurrent acute GVHD (skin and gut) according to NIH new GVHD categories.
- True
 - False
9. Treatment with extracorporeal photopheresis for patients with chronic GVHD:
- Is effective only when administered as primary treatment
 - Has a corticosteroid-sparing effect
 - Is simple to administer and relatively inexpensive
 - Results in higher responses in the skin including sclerotic features
 - A, B and C
 - B and D